多发性骨髓瘤中枢神经系统受累患者的病例对照研究
回顾性分析本中心2011年1月至2022年1月确诊的18例CNS-MM患者,与同期1∶3配对的初诊MM对照比较。CNS-MM自初诊中位发病14.2个月,累及CNS后中位OS仅3.8个月;初诊高LDH和髓外病灶是独立危险因素;以来那度胺或泊马度胺为基础的方案血液学+CNS缓解率高于硼替佐米或达雷妥尤单抗方案。
要点
- CNS-MM自初诊中位发病14.2个月,累及CNS后中位OS仅3.8个月。
- 初诊高LDH(HR=7.319)和髓外病灶(HR=8.054)是CNS-MM独立危险因素。
- 来那度胺或泊马度胺联合方案缓解率75.0%,高于硼替佐米或达雷妥尤单抗方案16.7%。
核心结论
- CNS-MM患者预后不佳,累及CNS后中位OS仅3.8个月。
- 初诊时高LDH或存在髓外病灶的患者发生CNS-MM的概率增高。
- 基于免疫调节剂的联合治疗可能改善CNS-MM患者的预后。
研究设计与样本
- 回顾性分析2011年1月至2022年1月在海军军医大学第二附属医院血液科确诊的18例CNS-MM患者初诊及CNS受累时临床资料。
- 与同期按1∶3配对的初诊MM患者(对照组)比较临床特征与生存差异。
主要发现
- CNS-MM自初诊中位发病时间14.2(0.9~79.6)个月,自初诊中位OS 30.5个月,累及CNS后中位OS仅3.8个月。
- 与对照组相比,CNS-MM患者IgD型多见(P=0.010)、贫血更严重(P=0.014)、骨髓浆细胞比例更高(P=0.013)、髓外病灶多见(P=0.001)、LDH增高(P=0.009)。
- 基于来那度胺或泊马度胺联合方案的血液学+CNS缓解率为75.0%,优于硼替佐米或达雷妥尤单抗联合方案的16.7%(P=0.019)。
- 同时存在2个高危因素(高LDH、髓外病灶)的初诊患者接受含免疫调节剂方案可显著降低CNS-MM发生率(P=0.026)。
- 初诊时高LDH(P=0.008,HR=7.319,95%CI 1.663~32.219)和髓外病灶(P=0.006,HR=8.054,95%CI 1.828~35.486)是发生CNS-MM的独立危险因素。
临床怎么用
- 作者认为,基于免疫调节剂的联合治疗可能改善CNS-MM患者的预后。
- 作者指出,初诊伴有高LDH或髓外病灶的患者发生CNS-MM的概率增高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the treatment options for multiple myeloma patients with central nervous system involvement (CNS-MM) , as well as their clinical characteristics and prognostic factors. Methods: Between January 2011 and January 2022 our center diagnosed 18 people with CNS-MM. A retrospective analysis was done on the clinical information from the initial diagnosis and central nervous system involvement, and it was compared to 1∶3 matched newly diagnosed MM from the same period. Analysis was done on the clinical characteristics and survival rates of the two groups. Results: In patients with CNS-MM, the median time of onset was 14.2 (0.9-79.6) months and the median overall survival (OS) was 30.5 months from initial diagnosis and only 3.8 months in patients after CNS involvement. The CNS-MM patients showed more IgD type (P=0.010) , severer anemia (P=0.014) , a higher proportion of bone marrow plasma cells (P=0.013) , more extramedullary lesions (P=0.001) , and increased lactic dehydrogenase (LDH) (P=0.009) when compared to the control group. Lenalidomide or pomalidomide-based combinations had higher rates of hematology and CNS remission than bortezomib or daratumumab-based regimens (75.0% vs 16.7% , P=0.019) . Patients who received IMiD-based regimens and had 2 high-risk factors at initial diagnosis (high LDH and extramedullary lesions) had a significantly lower incidence of CNS-MM (P=0.026) . At the initial diagnosis, LDH (P=0.008, HR=7.319, 95% CI 1.663-32.219) and extramedullary lesions (P=0.006, HR=8.054, 95% CI 1.828-35.486) were independent risk factors for the occurrence of CNS-MM. Conclusion: Patients with CNS-MM had a poor prognosis. Patients with high LDH or extramedullary lesions at the time of the initial diagnosis are more likely to have CNS-MM. The prognosis of this patient may be improved by immunoregulator-based therapy. 目的: 探讨累及中枢神经系统多发性骨髓瘤(CNS-MM)患者的临床特征、预后因素及治疗。 方法: 回顾性分析2011年1月至2022年1月在海军军医大学第二附属医院血液科确诊的18例CNS-MM患者在初诊及CNS受累时的临床资料,并与同时期按1∶3配对的初诊MM患者(对照组)比较,分析两组患者的临床特征、生存差异。 结果: CNS-MM自初诊时的中位发病时间为14.2(0.9~79.6)个月,中位总生存(OS)时间为30.5个月,累及CNS后的中位OS时间仅3.8个月。与对照组相比,CNS-MM患者IgD型多见(P=0.010)、贫血更严重(P=0.014)、骨髓浆细胞比例更高(P=0.013)、髓外病灶多见(P=0.001)、乳酸脱氢酶(LDH)增高(P=0.009)。基于来那度胺或泊马度胺联合方案的血液学+CNS缓解率优于硼替佐米或达雷妥尤单抗联合方案(75.0%对16.7%,P=0.019)。同时存在2个高危因素(高LDH、髓外病灶)的初诊患者,接受含免疫调节剂的方案可显著降低CNS-MM发生率(P=0.026)。初诊时高LDH(P=0.008,HR=7.319,95%CI 1.663~32.219)、存在髓外病灶(P=0.006,HR=8.054,95%CI 1.828~35.486)是发生CNS-MM的独立危险因素。 结论: CNS-MM患者预后不佳。初诊伴有高LDH或髓外病灶的患者发生CNS-MM的概率增高。基于免疫调节剂的联合治疗可能改善CNS-MM患者的预后。.
引用
- Li L, Feng ZY, Guo P, et al. [A case-control study of multiple myeloma patients with central nervous system involvement]. Zhonghua Xue Ye Xue Za Zhi. 2022. PMID: 36709107. doi:10.3760/cma.j.issn.0253-2727.2022.12.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。